Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial.
Gueyffier F, Subtil F, Bejan-Angoulvant T, Zerbib Y, Baguet JP, Boivin JM, Mercier A, Leftheriotis G, Gagnol JP, Fauvel JP, Giraud C, Bricca G, Maucort-Boulch D, Erpeldinger S; IDEAL Trial Group. Gueyffier F, et al. J Hum Hypertens. 2015 Jan;29(1):22-7. doi: 10.1038/jhh.2014.29. Epub 2014 Apr 17. J Hum Hypertens. 2015. PMID: 24739801 Clinical Trial.
[Drugs news].
Vrignaud L, Simon C, Agier MS, Bejan-Angoulvant T, Bouquet E, Beau-Salinas F, Jonville-Béra AP. Vrignaud L, et al. Arch Pediatr. 2017 Aug;24(8):783-787. doi: 10.1016/j.arcped.2017.05.008. Epub 2017 Jun 28. Arch Pediatr. 2017. PMID: 28668216 French. No abstract available.
[Endogenous and exogenous estrogens].
Bejan-Angoulvant T, Arnal JF. Bejan-Angoulvant T, et al. Presse Med. 2019 Nov;48(11 Pt 1):1244-1248. doi: 10.1016/j.lpm.2019.10.008. Epub 2019 Nov 12. Presse Med. 2019. PMID: 31732361 Review. French.
[Update on beta blockers in 2020].
Bejan-Angoulvant T, Angoulvant D. Bejan-Angoulvant T, et al. Rev Med Interne. 2020 Nov;41(11):741-747. doi: 10.1016/j.revmed.2020.04.007. Epub 2020 Jun 10. Rev Med Interne. 2020. PMID: 32532560 Review. French.
Evaluation of efficacy and safety of rituximab in combination with mycophenolate mofetil in patients with nonspecific interstitial pneumonia non-responding to a first-line immunosuppressive treatment (EVER-ILD): A double-blind placebo-controlled randomized trial.
Bejan-Angoulvant T, Naccache JM, Caille A, Borie R, Nunes H, Ferreira M, Cadranel J, Crestani B, Cottin V, Marchand-Adam S; OrphaLung. Bejan-Angoulvant T, et al. Respir Med Res. 2020 Nov;78:100770. doi: 10.1016/j.resmer.2020.100770. Epub 2020 May 23. Respir Med Res. 2020. PMID: 32777737 Clinical Trial.
[Drugs news].
Jonville-Béra AP, Bejan-Angoulvant T. Jonville-Béra AP, et al. Arch Pediatr. 2013 Jan;20(1):82-8. doi: 10.1016/j.arcped.2012.10.016. Epub 2012 Nov 27. Arch Pediatr. 2013. PMID: 23199562 French. No abstract available.
[Drugs news].
Bejan-Angoulvant T, Beau-Salinas F, Lengellé C, Cissoko H, Jonville-Béra AP. Bejan-Angoulvant T, et al. Arch Pediatr. 2014 Aug;21(8):897-901. doi: 10.1016/j.arcped.2014.05.008. Epub 2014 Jul 2. Arch Pediatr. 2014. PMID: 24997729 French. No abstract available.
98 results